Loading
Latest filing published 05 Jan 2024 for Oncternal Therapeutics, Inc., €5,367.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Rajesh Krishnan, listed as senior executive, appears in our data through filings on Oncternal Therapeutics, Inc. shares, published by SEC (Form 4). We count 5 filings; the first trade dates from 3 January 2022 and the latest from 3 January 2024.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 5 January 2024 with a share grant (€5,367) in Oncternal Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations